An interventional study of ICF in Takayasu Arteritis, sponsored by Pamukkale University. Completed at 1 site in Turkey. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2024-05-14.
Sponsored by Pamukkale University · Not applicable, Interventional, and Other
The aim was to analyze the problem in patients with Takayasu Arteritis based on the International Classification of Functioning, Disability and Health.The sample of our study will consist of individuals between the ages of 18-65 who have been diagnosed with Takayasu Arteritis by rheumatologists and are followed by Pamukkale University Rheumatology Clinic.
78 studies on the registry are indexed under Takayasu Arteritis; 32 are open to participants now.
This study's enrollment of 15 is below the median of 50 across 37 interventional studies indexed under Takayasu Arteritis.
Browse Takayasu Arteritis studies →Pamukkale University is the lead sponsor of 342 studies on the registry; 61 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Inclusion Criteria:-Being between the ages of 18-65
Exclusion Criteria:- Having another disease that affects your physical condition
Takayasu Arteritis patients between the ages of 18-65
Other: ICF
Matching the answers given to the question set consisting of 6 open-ended questions with ICF
6 open-ended questions
ICF
Time frame: 25 minutes
Plan to share: No
No publications or documents are linked to this record.
This study is completed, as verified in May 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.